Get the Stockscreener App
34.42
0.12%
-0.04
After Hours:
34.42
Dianthus Therapeutics Inc stock is traded at $34.42, with a volume of 738.08K.
It is down -0.12% in the last 24 hours and down -7.37% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$34.46
Open:
$34.56
24h Volume:
738.08K
Relative Volume:
1.17
Market Cap:
$1.11B
Revenue:
$4.85M
Net Income/Loss:
$-114.75M
P/E Ratio:
-10.59
EPS:
-3.25
Net Cash Flow:
$-100.36M
1W Performance:
-0.12%
1M Performance:
-7.37%
6M Performance:
+95.46%
1Y Performance:
+25.16%
1-Day Range:
$33.34
$34.90
1-Week Range:
$33.34
$36.68
52-Week Range:
$13.37
$40.16
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
34.42 | 1.37B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Published on: 2025-10-13 08:04:31 - newser.com
Can Dianthus Therapeutics Inc. stock hit analyst price targets2025 Top Decliners & Daily Growth Stock Investment Tips - newser.com
Published on: 2025-10-13 07:23:46 - newser.com
What analysts say about Dianthus Therapeutics Inc stockStock Split Announcements & Free Navigate Market With Precision - earlytimes.in
Is Dianthus Therapeutics Inc. (87E) stock at risk of policy regulationTake Profit & Fast Momentum Entry Tips - newser.com
When is the best time to exit Dianthus Therapeutics Inc.Earnings Trend Report & Weekly High Conviction Ideas - newser.com
How Dianthus Therapeutics Inc. stock benefits from global expansionTreasury Yields & Real-Time Stock Entry Alerts - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Is Dianthus Therapeutics Inc. (87E) stock a buy before new product rolloutQuarterly Growth Report & Fast Entry Momentum Trade Alerts - newser.com
Dianthus Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Performance Indicators - Markets Mojo
Volume spikes in Dianthus Therapeutics Inc. stock – what they meanMarket Sentiment Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Dianthus Therapeutics Inc. continue its uptrendInsider Buying & AI Enhanced Trading Signals - newser.com
Why Dianthus Therapeutics Inc. is moving todayTrade Risk Report & Free Long-Term Investment Growth Plans - newser.com
How Does Pritish Nandy Communications Ltd Compare to SP500 Over the Last 3 YearsFibonacci Extensions & Weekly Consultation With Financial Pros - earlytimes.in
What drives Dianthus Therapeutics Inc 87E stock priceDividend Growth Stocks & Free Expert Guidance For Growth - earlytimes.in
Advanced analytics toolkit walkthrough for Dianthus Therapeutics Inc.Market Sentiment Review & Safe Swing Trade Setup Alerts - newser.com
What Wall Street predicts for Dianthus Therapeutics Inc. stock priceQuarterly Earnings Report & Safe Capital Growth Tips - newser.com
What technical models suggest about Dianthus Therapeutics Inc.’s comebackJuly 2025 Rallies & Comprehensive Market Scan Reports - newser.com
Can Dianthus Therapeutics Inc. stock resist sector downturnsSell Signal & High Return Trade Opportunity Guides - newser.com
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.9%What's Next? - MarketBeat
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting - The Manila Times
Phase 2 Myasthenia Gravis Trial Results: Dianthus' Claseprubart Data to Be Unveiled at Major Conference - Stock Titan
Dianthus Therapeutics Hits New 52-Week High of $40.16 - Markets Mojo
What drives Okinawa Cellular Telephone Company OCU stock priceAnalyst Upgrades & High Profit Stock Alerts - earlytimes.in
Dianthus Therapeutics stock hits 52-week high at 40.0 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential - MSN
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target - MSN
Dianthus Therapeutics stock hits 52-week high at 40.0 USD - Investing.com
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year HighHere's Why - MarketBeat
What drives Dianthus Therapeutics Inc stock priceTechnical Resistance Breaks & Access Free Tools and Start Investing - earlytimes.in
Why retail investors pile into Dianthus Therapeutics Inc. stockPortfolio Growth Summary & Expert Approved Momentum Ideas - newser.com
What indicators show strength in Dianthus Therapeutics Inc.Market Sentiment Summary & Technical Entry and Exit Tips - newser.com
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dianthus Therapeutics Inc Stock (DNTH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Savitz Ryan | CFO & CBO |
Sep 09 '25 |
Sale |
35.00 |
20,000 |
700,000 |
0 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):